FDA Commissioner Dr. Makary on lifting HRT warnings: 50M women haven't experienced the benefits

Key Concepts

• Hormone Replacement Therapy (HRT): Treatment involving the administration of hormones, typically estrogen and progesterone, to alleviate menopausal symptoms and provide long-term health benefits.
• Women's Health Initiative (WHI) Study (2002): A large-scale study that initially reported increased risks of heart disease and breast cancer associated with HRT, leading to a significant decline in its use.
• Black Box Warnings: The most serious type of warning issued by the FDA, indicating potential for severe adverse effects.
• Estrogen and Progesterone: Hormones crucial for female reproductive health, levels of which decline during menopause.
• Menopause: The natural cessation of menstruation, typically occurring between ages 45 and 55, characterized by a decline in estrogen levels and various symptoms.
• Cardiovascular Disease (CVD): Diseases affecting the heart and blood vessels, a leading cause of death in women.
• Cognitive Decline and Alzheimer's Disease: Age-related deterioration of cognitive functions and a neurodegenerative disease characterized by progressive memory loss and cognitive impairment.
• Estrogen Receptors: Proteins found on cells that bind to estrogen, influencing cellular activity.
• Contraindications: Conditions or factors that make a particular treatment inadvisable.
• Perimenopause: The transitional period leading up to menopause, typically lasting 1-3 years before the final menstrual period.
• Cardioprotective Effect: A protective influence on the heart and cardiovascular system.
• Statins: A class of drugs used to lower cholesterol levels and reduce the risk of cardiovascular disease.

Re-evaluating Hormone Replacement Therapy: Removing Unwarranted Fears

This discussion centers on the FDA's decision to remove black box warnings from female hormone replacement therapy (HRT) products, a move driven by a re-evaluation of the risks and benefits of these treatments, particularly in light of the influential 2002 Women's Health Initiative (WHI) study. FDA Commissioner Dr. Marty McCary argues that these warnings have inappropriately deterred millions of women from accessing potentially beneficial therapies.

The Impact of the 2002 Women's Health Initiative Study

The 2002 WHI study, which investigated the effects of estrogen and progesterone therapy, generated significant public fear due to its findings that HRT users had a higher risk of heart disease and breast cancer. This led to a nearly 50% reduction in HRT use in the United States. Dr. McCary labels this a "real American tragedy," estimating that 50 million women have since been denied or convinced not to take HRT during menopause.

Critiques of the WHI Study and Evolving Understanding

Dr. McCary and other experts highlight critical flaws in the WHI study that led to its misinterpretation:

• Demographic: The study exclusively included women who were, on average, 10 years post-menopause with an average age of 63. This demographic is already at a higher risk for cardiovascular disease, making it difficult to isolate the effects of HRT.
• Delivery Method: Only one delivery method was evaluated: a daily pill combining estrogen and progesterone. Current HRT options include more bioidentical forms of estrogen and different progesterone formulations.
• Progesterone Type: The slight increase in breast cancer diagnoses observed in the WHI study was attributed to a specific type of progesterone called MPA (medroxyprogesterone acetate), which is no longer commonly used in HRT. Crucially, the study did not find an increase in breast cancer mortality.
• Timing of Initiation: Subsequent clinical trials have demonstrated that cardiovascular complications associated with HRT are a function of when the therapy is initiated. When started within 10 years of menopause onset, HRT can dramatically reduce heart disease risk.

Benefits of Hormone Replacement Therapy

Beyond alleviating menopausal symptoms, HRT offers significant long-term health benefits:

• Symptom Relief: HRT effectively addresses over 50 different menopausal symptoms, including hot flashes, night sweats, mood swings, and weight gain. 80% of women experience these symptoms, which can be severe and last for an average of eight years.
• Cardiovascular Health:
  • When initiated within 10 years of menopause, HRT can reduce heart disease risk by 30-50%.
  • One study showed a 48% reduction in heart attack deaths.
  • This is particularly significant as heart attacks are the leading cause of death in women.
  • Estrogen's cardioprotective effect is supported by historical observations, such as Mayo Clinic studies in the 1920s showing young women who had their ovaries removed experiencing severe heart disease later in life.
  • By comparison, statins reduce cardiovascular risk by 35%, while estrogen can reduce it by 30-50% in post-menopausal women.
• Cognitive Health: Studies suggest HRT can reduce cognitive decline by up to 64% and Alzheimer's disease by 35%.
• Bone Health: HRT can reduce the rate of bone fractures.

FDA's Rationale for Removing Black Box Warnings

The FDA's decision to remove black box warnings is based on the following:

• Misleading Information: The warnings were a result of "group think" and a "pile-on" effect following the WHI study, not a scientifically rational assessment of current HRT use.
• Empowering Women: The goal is to provide women with accurate information to make informed decisions about their health, moving away from a "fear machine" that discourages them from considering HRT.
• Addressing Historical Neglect: Dr. McCary emphasizes that women's health issues have historically been underappreciated and underfunded in a "paternalistic male culture dominated medical establishment." The FDA is committed to elevating these issues, citing the recent announcement on IVF as another example.

Contraindications and Nuanced Discussions

While advocating for broader consideration of HRT, the FDA acknowledges that it is not suitable for everyone. Contraindications include:

• An underlying predisposition to blood clots.
• Active breast cancer.
• A history of breast cancer where a doctor has concerns.
• Certain types of cancer with estrogen receptors, where an upregulated receptor could interact with the cancer.
• Generally, doctors do not prescribe HRT for individuals over age 60 or more than 10 years after the onset of menopause.

The key takeaway is that HRT should be a personalized conversation between a woman and her doctor, rather than a decision dictated by fear-inducing warnings.

The Historical Under-Education of Menopause

A significant contributing factor to the current situation is the historical lack of comprehensive education on menopause in medical schools. Due to the perceived risks associated with early HRT, menopause was often taught with minimal curriculum (around 2 minutes), leading to a situation where women are more likely to be prescribed antidepressants for menopausal mood swings than estrogen. This highlights a systemic issue where a common life event for women has been inadequately addressed by the medical community.

Conclusion

The FDA's move to remove black box warnings from HRT signifies a critical shift in understanding the risks and benefits of these therapies. The re-evaluation, driven by scientific advancements and a critique of the flawed WHI study, aims to empower women with accurate information. By dispelling unwarranted fears, the FDA seeks to ensure that women can engage in informed discussions with their healthcare providers and potentially access HRT for its significant menopausal symptom relief and long-term health benefits, particularly in cardiovascular and cognitive health, when deemed appropriate. This initiative is part of a broader effort to address historically neglected aspects of women's health.